RLD2302 clinical trials
Also written RLD2302.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2024
How each study uses RLD2302 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RLD2302
- 3
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses RLD2302 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy VolunteersCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT06518122Written as RLD2302
- A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed ConditionsCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT06357910Written as RLD2302
- A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy VolunteersCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT06346184Written as RLD2302